Literature DB >> 27150108

Knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis.

Li Xue1, Zhen Zhu, Ziming Wang, Hecheng Li, Peng Zhang, Zhenlong Wang, Qi Chen, Haiwen Chen, Tie Chong.   

Abstract

Chemoresistance is a serious problem for the treatment of androgen-independent prostate cancer (PC). The underlying molecular mechanisms by which androgen-independent PC cells acquire the capacity to proliferate remain largely unclear. The aim of this study was to investigate the biological role of prostaglandin reductase 1 (PTGR1) in prostate cancer. Data from the Oncomine database showed that PTGR1 is commonly upregulated in PC tissue in comparison to corresponding normal controls. Two PTGR1-specific short hairpin RNA (shRNA) sequences were used to block the expression of PTGR1 via a lentivirus-mediated system in the androgen-independent PC cell lines DU145 and PC 3. Functional analysis revealed that knockdown of PTGR1 significantly inhibited proliferation and colony formation by PC cells. The inhibition of cell proliferation was related to arrest of the cell cycle in the G0/G1 phase and increased apoptosis in response to PTGR1 knockdown as indicated by flow cytometry. PTGR1 silencing was found to mechanically enhance the expression of p21, caspase 3, and cleaved PARP and to decrease the level of cyclin D1. In conclusion, PTGR1 plays an essential role in PC cells and may be a potential therapeutic target for PC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27150108     DOI: 10.5582/bst.2016.01045

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  6 in total

1.  Exposure to an environmentally relevant phthalate mixture during prostate development induces microRNA upregulation and transcriptome modulation in rats.

Authors:  Wellerson R Scarano; Amina Bedrat; Luiz G Alonso-Costa; Ariana M Aquino; Bruno Fantinatti; Luis A Justulin; Luis F Barbisan; Paula P Freire; Jodi A Flaws; Lemos Bernardo
Journal:  Toxicol Sci       Date:  2019-06-14       Impact factor: 4.849

Review 2.  Malic enzyme 1 (ME1) in the biology of cancer: it is not just intermediary metabolism.

Authors:  Frank A Simmen; Iad Alhallak; Rosalia C M Simmen
Journal:  J Mol Endocrinol       Date:  2020-11       Impact factor: 5.098

3.  A novel urinary biomarker protein panel to identify children with ureteropelvic junction obstruction - A pilot study.

Authors:  Charan Kumar V Devarakonda; Emily R Shearier; Chaoran Hu; James Grady; Jeremy L Balsbaugh; John H Makari; Fernando A Ferrer; Linda H Shapiro
Journal:  J Pediatr Urol       Date:  2020-06-11       Impact factor: 1.830

4.  A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.

Authors:  Umesh Kathad; Aditya Kulkarni; Joseph Ryan McDermott; Jordan Wegner; Peter Carr; Neha Biyani; Rama Modali; Jean-Philippe Richard; Panna Sharma; Kishor Bhatia
Journal:  BMC Bioinformatics       Date:  2021-03-02       Impact factor: 3.169

5.  Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Authors:  Nina Zila; Andrea Bileck; Besnik Muqaku; Lukas Janker; Ossia M Eichhoff; Phil F Cheng; Reinhard Dummer; Mitchell P Levesque; Christopher Gerner; Verena Paulitschke
Journal:  Clin Proteomics       Date:  2018-03-09       Impact factor: 3.988

6.  PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.

Authors:  Wei Xia; Hansong Bai; Ying Deng; Yi Yang
Journal:  J Cell Mol Med       Date:  2020-09-27       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.